RxDoctor Payments Data

Angelia Felton-Wilks

Psychiatric/Mental Health · Milwaukee, WINPI 1669720041

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.3% of the total across 196 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 18.5% — the pattern of someone who eats at a lot of different presentations. Among psychiatric/mental health clinicians in WI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$4,425in general payments, 2019–2025

Across 196 payments — averaging $22.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$821
  • Otsuka America Pharmaceutical, Inc.$654
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$586
  • Axsome Therapeutics, Inc.$376
  • Johnson & Johnson$339
  • AstraZeneca$204
  • plus $1K from 25 others

What the payments were for

  • Food & beverage$4,35098%
  • Education$752%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,425 in reported general payments places this provider in the 90th percentile of 384 psychiatric/mental health providers in Wisconsin.

See all psychiatric/mental health providers in Wisconsin

Most prescribed under Part D

DrugClaimsCost to plans & patients
Austedo XrDeutetrabenazine16$115,404
VraylarCariprazine Hcl43$61,782
Invega SustennaPaliperidone Palmitate12$21,453
RexultiBrexpiprazole13$19,183
TrintellixVortioxetine Hydrobromide12$6,135
Ramelteon15$1,798
Aripiprazole33$648
Hydroxyzine Hcl35$569
Mirtazapine25$529
Duloxetine Hcl22$521
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine13$350
Guanfacine Hcl ErGuanfacine Hcl15$312
Escitalopram Oxalate51$308
Buspirone Hcl24$279
Trazodone Hcl44$256

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo Xr$56$115,40416 claims
AbbVieVraylar$821$61,78243 claims
Johnson & JohnsonInvega Sustenna$339$21,45312 claims
Otsuka America Pharmaceutical, Inc.Rexulti$654$19,18313 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$16$6,13512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 384 psychiatric/mental health providers in Wisconsin.

Other psychiatric/mental health in Milwaukee

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →